

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 40D2037283	(X3) Date Survey Completed 02/03/2026
Name of Provider or Supplier Quest Diagnostics Laboratorio Analisis Clinico	Street Address, City, State # 107 Calle Ortegon Caparra Gallery Suite 105, Guaynabo, PR	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	An offsite Proficiency Test (PT) Desk Review was performed on February 3, 2026 to Laboratorio Clinico Quest Diagnostics - Laboratorio de Anlisis Clinico, the laboratory was found out of compliance with the following conditions: 42 CFR 493.803 Proficiency Testing, Successful Participation 42 CFR 493.1403 Laboratory Director, Moderate complexity
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year</p>

	<p>2025), the laboratory failed to achieve satisfactory performance (80% or better) for two (2) out of three (3) consecutive testing events for the subspecialty of toxicology tests. Refer to D2118.</p>
<p>D2118</p>	<p>TOXICOLOGY CFR(s): 493.845(f)</p> <p>(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.</p> <p>This STANDARD is not met as evidenced by: Based on review of Regulation 9508 of the Puerto Rico Department of Health for the "Regulation, Establishment and Operation of Clinical Laboratories, Plasmapheresis Centers, Pathology Laboratory and Blood Banks", Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2025), the laboratory failed to achieve satisfactory performance (80% or better) for two (2) out of three (3) consecutive testing events for Valproic Acid analyte in the subspecialty of toxicology tests. The findings include: 1. Regulation 9508 of the Puerto Rico Department of Health established that all laboratories must be enrolled in the Puerto Rico Proficiency Testing Service Program, as their primary proficiency testing program. If the analyte is not offered, the laboratory must enroll in an additional program. 2. Review of the Casper Report 0155D and PRPTSP scores on January 26, 2026, confirmed that the laboratory had a PT (Proficiency Test) failure for the subspecialty of toxicology. The laboratory obtained the following testing scores: Analyte: Valproic Acid a. First testing event year 2025 - 60% b. Third testing event year 2025 - 40% 3. A review of the PRPTSP records confirmed the above findings.</p>
<p>D6000</p>	<p>MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403</p> <p>The laboratory must have a director who meets the qualification requirements of 493.1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart.</p> <p>This CONDITION is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER) 0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) scores (year 2025), the laboratory director failed to provide overall management and direction samples were tested as required. Refer to D6016.</p>
<p>D6016</p>	<p>LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i)</p> <p>(e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part;</p> <p>This STANDARD is not met as evidenced by: Based on review of Certification And Survey Provider Enhanced Reports (CASPER)</p>

0155D and Puerto Rico Proficiency Testing Service Program (PRPTSP) (year 2025), the laboratory director failed to ensure successful participation in an HHS-approved proficiency testing program. Refer to D2118.